Evogene (NASDAQ:EVGN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Lake Street Capital cut their price objective on shares of Evogene from $30.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, August 23rd.

Evogene Price Performance

Shares of NASDAQ EVGN opened at $1.69 on Tuesday. The stock has a market capitalization of $9.06 million, a PE ratio of -0.38 and a beta of 1.43. Evogene has a fifty-two week low of $1.44 and a fifty-two week high of $10.40. The business has a fifty day moving average price of $2.27 and a two-hundred day moving average price of $4.29.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC purchased a new stake in Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.